SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharmos (PARS)
PARS 2.700+13.6%Jan 21 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tom r. phillips who wrote (1360)12/20/2004 9:32:36 AM
From: NeuroInvestment  Read Replies (1) of 1386
 
$60 million plus in cash after BOL makes its payment.
The CB-2 platform is near PhI, and its value has gone up with the COX-2 snafu.

They aren't going to go bankrupt, and a quick look at some comparable companies in the CNS sector gives me a post-TBI value of 2.00.

But it's going to be a long time before it gets there--especially given the fact that management's recent stock sales are going to raise a lot of questions about 'who knew what when?' It will probably settle in the 1.00-1.50 range.

Another bitterly disappointing day in the neuroprotection world.

Harry
NeuroInvestment
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News